rs149688478
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_145207.3(SPATA5):c.1714+1G>A variant causes a splice donor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000138 in 1,606,370 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_145207.3 splice_donor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPATA5 | NM_145207.3 | c.1714+1G>A | splice_donor_variant | ENST00000274008.5 | NP_660208.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AFG2A | ENST00000274008.5 | c.1714+1G>A | splice_donor_variant | 1 | NM_145207.3 | ENSP00000274008 | P1 | |||
AFG2A | ENST00000422835.2 | n.1756+1G>A | splice_donor_variant, non_coding_transcript_variant | 1 | ||||||
AFG2A | ENST00000675612.1 | c.1711+1G>A | splice_donor_variant | ENSP00000502453 | ||||||
AFG2A | ENST00000674886.1 | n.1776+1G>A | splice_donor_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152226Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000928 AC: 23AN: 247722Hom.: 0 AF XY: 0.0000970 AC XY: 13AN XY: 134020
GnomAD4 exome AF: 0.000134 AC: 195AN: 1454144Hom.: 0 Cov.: 31 AF XY: 0.000138 AC XY: 100AN XY: 722768
GnomAD4 genome AF: 0.000171 AC: 26AN: 152226Hom.: 0 Cov.: 32 AF XY: 0.000134 AC XY: 10AN XY: 74376
ClinVar
Submissions by phenotype
Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Feb 02, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with epilepsy, hearing loss, and intellectual disability syndrome (MIM#616577). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0211 - Canonical splice site variant without proven consequence on splicing (no functional evidence available). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (45 heterozygotes, 0 homozygotes). (SP) 0505 - Abnormal splicing is predicted by in silico tools and affected nucleotide is highly conserved. (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported multiple times as pathogenic, and observed in compound heterozygous state in several individuals with microcephaly, intellectual disability, seizures and/or hearing loss (ClinVar, LOVD, DECIPHER, PMID: 26299366, PMID: 28293831). (SP) 0901 - This variant has strong evidence for segregation with disease. This variant has segregated with disease, in two pairs of affected siblings (PMID: 26299366, PMID: 28293831). (SP) 1206 - This variant has been shown to be paternally inherited (by trio analysis). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 31, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 05, 2024 | Variant summary: SPATA5 (or AFG2A) c.1714+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes the canonical 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 9.3e-05 in 247722 control chromosomes (gnomAD). c.1714+1G>A has been reported in the literature in the compound heterozygous state in individuals affected with Epilepsy, Hearing Loss, And Mental Retardation Syndrome and segregated with the disease phenotype in at least one family (e.g. Tanaka_2015, Szczauba_2017). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 28293831, 26299366). ClinVar contains an entry for this variant (Variation ID: 207803). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 18, 2022 | This sequence change affects a donor splice site in intron 9 of the SPATA5 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SPATA5 are known to be pathogenic (PMID: 26299366). This variant is present in population databases (rs149688478, gnomAD 0.03%). Disruption of this splice site has been observed in individual(s) with epilepsy, hearing loss, and intellectual disability syndrome (PMID: 26299366, 28293831). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 207803). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 13, 2022 | The c.1714+1G>A intronic variant results from a G to A substitution one nucleotide(s) after coding exon 9 of the SPATA5 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on data from gnomAD, the A allele has an overall frequency of 0.02% (45/279128) total alleles studied. The highest observed frequency was 0.03% (40/127602) of European (non-Finnish) alleles. This mutation has been confirmed in trans with a second SPATA5 alteration in two families with children with microcephaly, developmental delay, seizures, and sensorineural hearing loss (Tanaka, 2015; Szczauba, 2017). Based on the available evidence, this alteration is classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2020 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at